MYnd Analytics, Inc. (MYND), a behavioral health company with tools and technologies aimed at improving the delivery of mental health services through the combination of telemedicine and data analytics, today announced that certain investors have agreed to purchase approximately $2.8 million of the Company’s common stock in a registered direct offering. The Company entered into a securities purchase agreement with the investors pursuant to which the Company agreed to sell 2,776,491 shares of its common stock at a per share price of $1.02. The Company intends to use the net proceeds for general corporate purposes.

MYnd Analytics, Inc. (MYND), a behavioral health company with tools and technologies aimed at improving the delivery of mental health services through the combination of telemedicine and data analytics, today announced that Arcadian Telepsychiatry, a wholly owned subsidiary of MYnd, has signed an agreement with Memorial to provide telebehavioral health services through its provider network beginning in May. Memorial is one of the most comprehensive healthcare systems in the state, licensed for 303 beds, including a state-designated level II trauma center, two outpatient surgery centers, satellite diagnostic and rehabilitation centers and over 95 physician clinics.

MYnd Analytics, Inc. (MYND), a behavioral health company with tools and technologies aimed at improving the delivery of mental health services through the combination of telemedicine and data analytics, today announced that its wholly owned subsidiary, Arcadian Telepsychiatry Services LLC, has partnered with Care Compass Network (CCN), to offer telepsychiatry and teletherapy services, through Arcadian’s provider network.

MYnd Analytics, Inc. (MYND), a behavioral health company with tools and technologies aimed at improving the delivery of mental health services through the combination of telemedicine and data analytics, today announced an interview with its Chairman of the Board, Robin L. Smith, MD, MBA, aired on The RedChip Money Report television program. In the exclusive interview, Dr. Smith discussed MYnd Analytics recent developments, key industry trends and growth drivers, as well as insight regarding the Company’s acquisition of Emmaus and its FDA-approved sickle cell treatment. MYnd Analytics, Inc. (www.myndanalytics.com), with its wholly owned subsidiary Arcadian Telepsychiatry Services LLC, is a technology-enabled telepsychiatry and teletherapy company that provides enhanced access to behavioral health services, improves patient outcomes and helps lower the costs associated with behavioral health issues.

NEW YORK, NY / ACCESSWIRE / April 26, 2019 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New ...

MYnd Analytics, Inc. (MYND), a behavioral health company with tools and technologies aimed at improving the delivery of mental health services through the combination of telemedicine and data analytics, today announced an interview with its Chairman of the Board, Robin L. Smith, MD, MBA, will air on The RedChip Money Report television program. The interview will air Sunday, April 21, on Bloomberg International, available in 149 million homes across Europe, the Middle East, and Africa. In the exclusive interview, Dr. Smith discusses MYnd Analytics’ recent developments, key industry trends and growth drivers, as well as insight regarding the Company’s acquisition of Emmaus and its FDA-approved sickle cell treatment.

MYnd Analytics, Inc. (MYND), a behavioral health company with tools and technologies aimed at improving the delivery of mental health services through the combination of telemedicine and data analytics, today announced that Patrick Herguth, Chief Executive Officer, is scheduled to present at the ThinkEquity Conference on Thursday, May 2, at 11:00 AM Eastern Time being held at The Mandarin Oriental Hotel in New York City. MYnd Analytics, Inc. (www.myndanalytics.com), with its wholly owned subsidiary Arcadian Telepsychiatry Services LLC, is a technology-enabled telepsychiatry and teletherapy company that provides enhanced access to behavioral health services, improves patient outcomes and helps lower the costs associated with behavioral health issues.

MYnd Analytics, Inc. (MYND), a behavioral health company with tools and technologies aimed at improving the delivery of mental health services through the combination of telemedicine and data analytics, will host an investor webinar and live Q&A session on Thursday, April 4, at 11:00 a.m. EST. The webinar will feature a presentation by CEO Patrick Herguth and Chairman Robin L. Smith, MD, MBA discussing MYnd Analytics’ recent developments, key industry trends and growth drivers, as well as insight regarding the Company’s acquisition of Emmaus and its FDA-approved sickle cell treatment. MYnd Analytics, Inc. (www.myndanalytics.com), with its wholly owned subsidiary Arcadian Telepsychiatry Services LLC, is a technology-enabled telepsychiatry and teletherapy company that provides enhanced access to behavioral health services, improves patient outcomes and helps lower the costs associated with behavioral health issues.

MYnd Analytics, Inc. (MYND), a behavioral health company with tools and technologies aimed at improving the delivery of mental health services through the combination of telemedicine and data analytics, today announced it has received its first notice of patent allowance in Europe on the Company’s neuromodulation platform for predicting patients likely to respond to Transcranial Magnetic Stimulation (TMS). The allowed patent application is entitled “Method for Assessing the Susceptibility of a Human Individual Suffering from a Psychiatric or Neurological Disorder to Neuromodulation Treatment,” and has an anticipated expiration date in 2029. The patent has as its subject matter the Company’s proprietary process and proprietary outcome data on the use of individualized Quantitative EEG (QEEG) features to predict non-response of individuals to TMS therapy.

MYnd Analytics, Inc. (MYND), a predictive analytics and telehealth company aimed at improving the delivery of mental health through the combination of telemedicine and data analytics, today announced that its wholly owned subsidiary, Arcadian Telepsychiatry Services LLC, has been invited to present at the 2019 Telemed Leadership Forum, entitled, “Transforming Healthcare Delivery,” in Washington, DC, on April 3-5, 2019. The Forum is hosted by the Utilization Review Accreditation Commission (URAC).

CORAL GABLES, FL / ACCESSWIRE / March 13, 2019 / The future of the tech stock market directly related to the ability of companies in the tech industry to combat the growing obstacles facing humanity. In ...

MYnd Analytics, Inc. (MYND), a predictive analytics company aimed at improving the delivery of mental health through the combination of telemedicine and data analytics, today announced that its wholly owned subsidiary, Arcadian Telepsychiatry Services LLC, has joined the Magellan Healthcare behavioral health provider network to offer telepsychiatry, teletherapy and teleEAP services to its members through Arcadian’s provider network.

MYnd Analytics, Inc. (MYND), a market leader in improving the delivery of mental health through the combination of telemedicine and data analytics/augmented intelligence, today announced a partnership with IMPACT Solutions, a leading provider of behavior healthcare and Employee Assistance Programs (EAP) with a broad range of clients across the Midwest, as well as nationally. Under the agreement, Arcadian will provide tele-EAP services for IMPACT Solutions’ customers through its provider network.

NEW YORK , Feb. 26, 2019 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...

MYnd Analytics, Inc. (MYND), a predictive analytics company aimed at improving the delivery of mental health through the combination of telemedicine and data analytics, today provided the following business update and letter to shareholders from the Company’s CEO, Patrick Herguth. The Company also reported it has filed its quarterly report on Form 10-Q for the period ending December 31, 2018, which is available at: www.sec.gov.

MYnd Analytics, Inc. (MYND), a predictive analytics company aimed at improving the delivery of mental health through the combination of telemedicine and data analytics, today announced that the U.S. General Services Administration has awarded a five-year Federal Supply Schedule (FSS) contract as a government supplier, effective January 31, 2019 with the opportunity to renew it for 15 more years. Under the contract, MYnd intends to offer Healthcare Information Technology services to federal government departments and agencies related to our Psychiatric EEG Evaluation Registry, including the Department of Defense and the United States Department of Veterans Affairs (VA) facilities nationwide.

What percentage of MYnd (to be renamed “Emmaus Life Sciences, Inc.” and referred to as “New Emmaus”) will current MYnd Analytics (“MYnd”) shareholders own upon completion of the transaction? MYnd shareholders will own 5.9% of the fully diluted shares of Emmaus post closing.

While small-cap stocks, such as MYnd Analytics, Inc. (NASDAQ:MYND) with its market cap of US$7.8m, are popular for their explosive growth, investors should also be aware of their balance sheet
Read More...

MYnd Analytics, Inc. (MYND), a predictive analytics company aimed at improving the delivery of mental health through the combination of telemedicine and data analytics, today announced that Patrick Herguth will be joining the team as Chief Executive Officer and has also been appointed to the Board of Directors. George Carpenter will assume the new role of Chief Innovation Officer.

MYnd Analytics, Inc. (MYND), a market leader in improving the delivery of mental health through the combination of telemedicine and data analytics/augmented intelligence, today announced that it has been awarded a subcontract to incorporate its PEER report within a project to develop a suicide prevention toolkit, for the U.S. Department of Health and Human Services (HHS). George Carpenter, CEO of MYnd stated, “We are honored to be a part of this important project, which involves development of a suicide prevention tool kit for HHS. Importantly, we look forward to leveraging our expertise and the extensive data we have compiled through the PEER registry.

MYnd Analytics, Inc. (MYND), a market leader in improving the delivery of mental health through the combination of telemedicine and data analytics/augmented intelligence, today announced that the Company’s Psychiatric EEG Evaluation Registry (“PEER”) was featured on CBS New York by medical correspondent Dr. Max Gomez. MYnd Analytics, Inc. (www.myndanalytics.com) is a predictive analytics company that has developed a decision support tool to help physicians reduce trial and error treatment in mental health and provide more personalized care to patients.